Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) EBIT (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed EBIT for 6 consecutive years, with -$15.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT fell 60.62% year-over-year to -$15.1 million, compared with a TTM value of -$82.4 million through Sep 2025, down 27.59%, and an annual FY2024 reading of -$68.0 million, up 19.0% over the prior year.
  • EBIT was -$15.1 million for Q3 2025 at Barinthus Biotherapeutics, up from -$23.3 million in the prior quarter.
  • Across five years, EBIT topped out at $13.2 million in Q2 2022 and bottomed at -$26.3 million in Q2 2023.
  • Average EBIT over 5 years is -$13.9 million, with a median of -$16.9 million recorded in 2024.
  • The sharpest move saw EBIT surged 230.71% in 2022, then plummeted 3385.02% in 2023.
  • Year by year, EBIT stood at -$16.7 million in 2021, then tumbled by 50.55% to -$25.1 million in 2022, then rose by 20.34% to -$20.0 million in 2023, then decreased by 17.02% to -$23.4 million in 2024, then skyrocketed by 35.59% to -$15.1 million in 2025.
  • Business Quant data shows EBIT for BRNS at -$15.1 million in Q3 2025, -$23.3 million in Q2 2025, and -$20.6 million in Q1 2025.